Literature DB >> 20600632

Targeting Notch signaling pathway to overcome drug resistance for cancer therapy.

Zhiwei Wang1, Yiwei Li, Aamir Ahmad, Asfar S Azmi, Sanjeev Banerjee, Dejuan Kong, Fazlul H Sarkar.   

Abstract

Chemotherapy is an important therapeutic strategy for cancer treatment and remains the mainstay for the management of human malignancies; however, chemotherapy fails to eliminate all tumor cells because of intrinsic or acquired drug resistance, which is the most common cause of tumor recurrence. Recently, emerging evidences suggest that Notch signaling pathway is one of the most important signaling pathways in drug-resistant tumor cells. Moreover, down-regulation of Notch pathway could induce drug sensitivity, leading to increased inhibition of cancer cell growth, invasion, and metastasis. This article will provide a brief overview of the published evidences in support of the roles of Notch in drug resistance and will further summarize how targeting Notch by "natural agents" could become a novel and safer approach for the improvement of tumor treatment by overcoming drug resistance.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20600632      PMCID: PMC2955995          DOI: 10.1016/j.bbcan.2010.06.001

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  122 in total

1.  Off the beaten pathway: the complex cross talk between Notch and NF-kappaB.

Authors:  Clodia Osipo; Todd E Golde; Barbara A Osborne; Lucio A Miele
Journal:  Lab Invest       Date:  2007-12-03       Impact factor: 5.662

Review 2.  Notch signaling.

Authors:  Lucio Miele
Journal:  Clin Cancer Res       Date:  2006-02-15       Impact factor: 12.531

3.  Notch-1 and notch-4 receptors as prognostic markers in breast cancer.

Authors:  Katharine Yao; Paola Rizzo; Prabha Rajan; Kathy Albain; Karen Rychlik; Sneha Shah; Lucio Miele
Journal:  Int J Surg Pathol       Date:  2010-05-05       Impact factor: 1.271

4.  Cross-talk between Notch and EGFR signaling in human breast cancer cells.

Authors:  Jianjian Dai; Daoxin Ma; Shaolei Zang; Dongmei Guo; Xun Qu; Jingjing Ye; Chunyan Ji
Journal:  Cancer Invest       Date:  2009-06       Impact factor: 2.176

Review 5.  The role of KRAS mutations in resistance to EGFR inhibition in the treatment of cancer.

Authors:  Ariel Lopez-Chavez; Corey A Carter; Giuseppe Giaccone
Journal:  Curr Opin Investig Drugs       Date:  2009-12

6.  Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells.

Authors:  Yiwei Li; Timothy G VandenBoom; Dejuan Kong; Zhiwei Wang; Shadan Ali; Philip A Philip; Fazlul H Sarkar
Journal:  Cancer Res       Date:  2009-08-04       Impact factor: 12.701

Review 7.  Targeting multidrug resistance in cancer.

Authors:  Gergely Szakács; Jill K Paterson; Joseph A Ludwig; Catherine Booth-Genthe; Michael M Gottesman
Journal:  Nat Rev Drug Discov       Date:  2006-03       Impact factor: 84.694

Review 8.  Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers.

Authors:  Michèle Sabbah; Shahin Emami; Gérard Redeuilh; Sylvia Julien; Grégoire Prévost; Amazia Zimber; Radia Ouelaa; Marc Bracke; Olivier De Wever; Christian Gespach
Journal:  Drug Resist Updat       Date:  2008-08-20       Impact factor: 18.500

Review 9.  Leukemic stem cells: from metabolic pathways and signaling to a new concept of drug resistance targeting.

Authors:  Jan Styczynski; Tomasz Drewa
Journal:  Acta Biochim Pol       Date:  2007-12-13       Impact factor: 2.149

10.  Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non-small cell lung carcinoma.

Authors:  Barbara A Frederick; Barbara A Helfrich; Christopher D Coldren; Di Zheng; Dan Chan; Paul A Bunn; David Raben
Journal:  Mol Cancer Ther       Date:  2007-05-31       Impact factor: 6.261

View more
  102 in total

1.  Epithelial-mesenchymal transition, the tumor microenvironment, and metastatic behavior of epithelial malignancies.

Authors:  Lindsay J Talbot; Syamal D Bhattacharya; Paul C Kuo
Journal:  Int J Biochem Mol Biol       Date:  2012-05-18

Review 2.  Novel therapeutic targets for pancreatic cancer.

Authors:  Shing-Chun Tang; Yang-Chao Chen
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

3.  Nitric oxide-targeted therapy inhibits stemness and increases the efficacy of tamoxifen in estrogen receptor-positive breast cancer cells.

Authors:  Laura M López-Sánchez; Rafael Mena; Silvia Guil-Luna; Ana Mantrana; Jon Peñarando; Marta Toledano-Fonseca; Francisco Conde; Juan R De la Haba-Rodríguez; Enrique Aranda; Antonio Rodríguez-Ariza
Journal:  Lab Invest       Date:  2020-12-01       Impact factor: 5.662

4.  Notch Signaling Pathway in Pancreatic Cancer Progression.

Authors:  Jia Ma; Jun Xia; Lucio Miele; Fazlul H Sarkar; Zhiwei Wang
Journal:  Pancreat Disord Ther       Date:  2013-05-30

Review 5.  Investigational Notch and Hedgehog inhibitors--therapies for cardiovascular disease.

Authors:  Eileen M Redmond; Shaunta Guha; Dermot Walls; Paul A Cahill
Journal:  Expert Opin Investig Drugs       Date:  2011-10-18       Impact factor: 6.206

Review 6.  The two faces of FBW7 in cancer drug resistance.

Authors:  Zhiwei Wang; Hidefumi Fukushima; Daming Gao; Hiroyuki Inuzuka; Lixin Wan; Alan W Lau; Pengda Liu; Wenyi Wei
Journal:  Bioessays       Date:  2011-08-30       Impact factor: 4.345

7.  γ-secretase inhibition combined with cisplatin enhances apoptosis of nasopharyngeal carcinoma cells.

Authors:  Jun-Xu Zhou; Ji-Bo Han; Shi-Ming Chen; Yu Xu; Yong-Gang Kong; Bo-Kui Xiao; Ze-Zhang Tao
Journal:  Exp Ther Med       Date:  2011-12-06       Impact factor: 2.447

8.  Obesity induced a leptin-Notch signaling axis in breast cancer.

Authors:  Monica Battle; Corey Gillespie; Alexander Quarshie; Viola Lanier; Tia Harmon; Kaamilah Wilson; Marta Torroella-Kouri; Ruben R Gonzalez-Perez
Journal:  Int J Cancer       Date:  2013-10-08       Impact factor: 7.396

Review 9.  Therapeutic modulation of Notch signalling--are we there yet?

Authors:  Emma R Andersson; Urban Lendahl
Journal:  Nat Rev Drug Discov       Date:  2014-05       Impact factor: 84.694

10.  A novel inhibitor of ADAM17 sensitizes colorectal cancer cells to 5-Fluorouracil by reversing Notch and epithelial-mesenchymal transition in vitro and in vivo.

Authors:  Dan-Dan Li; Chang-Hao Zhao; Huai-Wei Ding; Qiong Wu; Tian-Shu Ren; Jian Wang; Cong-Qin Chen; Qing-Chun Zhao
Journal:  Cell Prolif       Date:  2018-08-02       Impact factor: 6.831

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.